ChromaDex (NASDAQ:CDXC) Sets New 12-Month High - Here's Why

Shares of ChromaDex Co. (NASDAQ:CDXC - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $7.42 and last traded at $7.24, with a volume of 388322 shares traded. The stock had previously closed at $7.01.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CDXC. HC Wainwright raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, November 4th. StockNews.com downgraded shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, Roth Mkm upped their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th.

ChromaDex Stock Performance

The firm has a market capitalization of $566.74 million, a price-to-earnings ratio of 742.74 and a beta of 1.88. The company has a 50-day moving average price of $3.90 and a 200-day moving average price of $3.36.

ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the previous year, the firm earned ($0.01) EPS. On average, research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.64% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CDXC. Miracle Mile Advisors LLC purchased a new position in shares of ChromaDex in the 2nd quarter valued at about $27,000. The Manufacturers Life Insurance Company purchased a new position in ChromaDex in the second quarter valued at about $31,000. Merriman Wealth Management LLC acquired a new stake in shares of ChromaDex during the 2nd quarter valued at approximately $32,000. Lazard Asset Management LLC purchased a new stake in shares of ChromaDex during the 1st quarter worth approximately $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the 1st quarter worth approximately $54,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.